Topical montelukast for treatment of atopic dermatitis

a technology for atopic dermatitis and montelukast, which is applied in the direction of macromolecular non-active ingredients, active ingredients of heterocyclic compounds, organic active ingredients, etc., can solve the problems of montelukast sodium exerting additional challenge to be formulated, abnormal and dryness, and affecting the chemical stability of this substan
US20200237651A1Inactive Publication Date: 2020-07-30TARO PHARMA INDS
2 Cites 3 Cited by

Patent Information

Authority / Receiving Office
US · United States
Patent Type
Applications(United States)
Current Assignee / Owner
TARO PHARMA INDS
Publication Date
2020-07-30
Estimated Expiration
Not applicable · inactive patent

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

A topical formulation comprising Montelukast or a pharmaceutically acceptable salt thereof, a gelling agent and water for the treatment of atopic dermatitis.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] This application claims priority to the U.S. Provisional Patent Application No. 62 / 331,528 filed on May 4, 2016, the disclosure of which is incorporated by reference herein.BACKGROUND

[0002] Atopic dermatitis is an increasingly common pruritic, chronic, inflammatory skin disorder. There has been a striking rise in the incidence of Atopic dermatitis (AD) during the past two decades, which is not simply due to an increased recognition of the disease. Population studies suggest that in most countries, AD now affects at least 10-20% of children at some point during childhood. In particular, higher prevalence has been recorded in urban regions than in rural regions of development countries, and the disease is more common in higher social class groups, suggesting that environmental factors associated with more industrialized and urban living determine expression of AD.

[0003] There are pathogenic mechanisms that are in common to both AD and asthma. The exaggerated inflammatory response ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More